Pathalys Pharma: Valuation, Funding & Investors
4242 Six Forks Road Suite 820 Raleigh, North Carolina 27609, UShttps://www.pathalys.com/Therapeutics
Pathalys Pharma is a private biopharmaceutical company focused on the late-stage development of innovative treatments for kidney disease. The company is advancing its lead product, upacicalcet, towards NDA submission and pre-commercialization, aiming to address unmet medical needs in nephrology.
Leadership & Board
- Current Number of Employees
- 18
- Current LinkedIn Followers
- 1,637
Latest Estimated Valuation
- Total Amount Raised
- $105M
- Total Funding Rounds
- 1
- Latest Funding Amount
- $105M
- Latest Funding Round
- Series B
Company Momentum Positive
Articles Published on TipRanks4
LinkedIn Trend+3.28% followers
Workforce Trend+0.0% employees
Pathalys Pharma LinkedIn following is increasing, signaling rising market interest, while its workforce is growing, indicating business expansion.
Employee Trend
Pathalys Pharma had 18 employees as of October 26, 2026. The number of employees increased by 0 (0.00%) week-over-week.
18Latest Employee Count
0(0.00%)Week-Over-Week Change
Social Trend
Pathalys Pharma had 1,637 followers as of October 26, 2026. The number of followers increased by 52 (3.28%) week-over-week.
1,637Latest Followers Count
52(3.28%)Week-Over-Week Change
Funding Round
| Funding Date | Funding Round | Amount Raised | Post-Money Valuation |
|---|---|---|---|
| Aug 20, 2024 | Series B | $105.00M | ― |
Investors
| Investor Name | Funding Round |
|---|---|
| TCGX | Series B |
| JP Morgan Life Sciences Private Capital | Series B |
| Samsara BioCapital | Series B |
| Marshall Wace | Series B |
| KB Investment | Series B |
| JPS Growth Investment Limited Partnership | Series B |
| Catalys Pacific | Series B |
| DaVita Venture Group | Series B |
Similar Companies
Related News and Analysis
